Premium
Preoperative albumin‐to‐globulin ratio predicts survival in patients with non‐small‐cell lung cancer after surgery
Author(s) -
Zhang Hua,
Zhang Bin,
Zhu Kaikai,
Wu Chao,
Gao Liuwei,
Sun Xiaoyan,
Liu Chang,
Wang Changli
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26766
Subject(s) - medicine , stage (stratigraphy) , chemotherapy , lung cancer , multivariate analysis , oncology , gastroenterology , globulin , albumin , receiver operating characteristic , surgery , paleontology , biology
The prognostic value of the preoperative albumin‐to‐globulin ratio (AGR) has not been investigated in non‐small‐cell lung cancer (NSCLC). Therefore, we aimed to assess the clinical applicability of the preoperative AGR to predict the prognosis in patients with NSCLC. We retrospectively enrolled 545 patients with stage I/II/III NSCLC who underwent surgery at our institution. The cutoff value for preoperative AGR was calculated by using a receiver operating characteristic curve analysis. A low AGR was associated with several clinicopathological variables related to tumor progression. In the multivariate analyses, the preoperative AGR was identified as an independent prognostic factor for disease‐free survival (DFS; P = 0.003) and overall survival (OS; P = 0.005). For patients with stage II and III with a preoperative AGR ≤ 1.43, the surgery plus chemotherapy group had a significantly longer DFS and OS than the surgery alone group ( P = 0.002 and P = 0.001, respectively); however, a significant difference in DFS and OS between these two groups was not observed in patients with stage II and III with an AGR > 1.43 ( P = 0.808 and P = 0.842, respectively). The preoperative AGR is an independent, significant predictor of DFS and OS in patients with NSCLC. Our results also demonstrate that the preoperative AGR might be a predictive marker of the therapeutic effect of postoperative chemotherapy in patients with stage II and III NSCLC.